First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or ga

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Li

AI-driven hiring and HR automation are reshaping HCM software, with three companies, namely, PAYC, P

HUTCHMED reported positive Phase 2 data for fanregratinib in advanced ICC as China reviews the drug.

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving

SEATTLE--(BUSINESS WIRE)--Syndio, the Decision Intelligence for Pay company, today announced the acq

LAS VEGAS, June 16, 2026 (GLOBE NEWSWIRE) -- Connect For Partners -- isolved ® today unveiled the fi

– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Cons

LAS VEGAS, June 15, 2026 (GLOBE NEWSWIRE) -- Connect for Partners – isolved®, a provider of human ca

LAS VEGAS, June 15, 2026 (GLOBE NEWSWIRE) -- Connect For Partners – isolved, a provider of human cap

Paychex named a leading HCM provider to TIME's America's Top WorkTech Companies 2026 List List ident

— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile ——The

— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile — —Th

U.S. Office of Personnel Management Selects Oracle to Power Federal Workforce Modernization PR Newsw

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of  MYBPC3-Associated HCM Benefit

SOUTH SAN FRANCISCO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TN

HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHM

Companies granted approval by the China National Medical Products Administration ("NMPA") fo

Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2

Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2

HiBob recognized as an ISG Vendor of Excellence for its comprehensive Human Capital Management Suite

HiBob recognized as an ISG Vendor of Excellence for its innovative HCM Platform, highlighting its ab

Investigational New Drug application for KHN921 received “study may proceed” from the US FDA. KHN921

HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that the New

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) L

B of A Securities analyst Dimple Gosai maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and low

HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM; HKEX:13) tod

HUTCHMED (China) (NASDAQ:HCM) reported quarterly earnings of $2.62 per share which beat the analyst

First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced

HUTCHMED reported positive Phase 3 trial results for sovleplenib in autoimmune anemia, supporting a

NDA supported by results from a Phase II registration trial in China —— Second most common form of l

— First-in-human trial of candidate from the next-generation ATTC platform —— Simultaneous China and

— HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with syner

First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent ta

new and updated data from several studies of compounds discovered by HUTCHMED will be presented at t

Morgan Stanley analyst Jack Lin downgrades HUTCHMED (China) (NASDAQ:HCM) from Equal-Weight to Und

B of A Securities analyst Dimple Gosai maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and rai

Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or de

— The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significan

The China's National Medical Products Administration ("NMPA") has granted Breakthrough T

SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO®

Hutchmed forecasts 2025 oncology revenue of $350–$450 million after a strong 65% growth in 2024, dri

FINANCIAL GUIDANCEHUTCHMED provides full year 2025 guidance for Oncology/Immunology consolidated rev

HUTCHMED (China) (NASDAQ:HCM) reported quarterly earnings of $0.22 per share. This is a 62.07 percen